Andreas Reiter
III. Medizinische Universitätsklinik
Fakultät für Klinische Medizin Mannheim der Universität Heidelberg
Wiesbadener Str. 7-11
68305 Mannheim
Germany
[email]@*.ma.uni-heidelberg.de
Name/email consistency: high
- Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. Reiter, A., Walz, C., Cross, N.C. Curr. Drug. Targets (2007)
- The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Reiter, A., Walz, C., Watmore, A., Schoch, C., Blau, I., Schlegelberger, B., Berger, U., Telford, N., Aruliah, S., Yin, J.A., Vanstraelen, D., Barker, H.F., Taylor, P.C., O'Driscoll, A., Benedetti, F., Rudolph, C., Kolb, H.J., Hochhaus, A., Hehlmann, R., Chase, A., Cross, N.C. Cancer Res. (2005)
- Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia. Reiter, A., Lengfelder, E., Grimwade, D. Acta Haematol. (2004)
- AraC-based pharmacotherapy of chronic myeloid leukaemia. Reiter, A., Hochhaus, A., Berger, U., Kuhn, C., Hehlmann, R. Expert. Opin. Pharmacother (2001)